For Immediate Release
Contact: Stuart Heiser
202-828-0059
sheiser@aamc.org

Ad Hoc Group Statement on the Passage of Continuing Resolution Through Feb. 18

December 3, 2021 – The Ad Hoc Group for Medical Research issued the following statement in response to passage by the House and Senate of H.R. 6119, a bill to extend fiscal year (FY) 2021 funding for federal operations temporarily through February 18, 2022:

Patients across the country and the world rely on critical medical research taking place in labs in every state with support from the National Institutes of Health (NIH). Despite strong, longstanding bipartisan support for increasing the investment in NIH funding, including in FY 2022, the agency will remain in budget limbo months into the fiscal year and amid the ongoing COVID-19 pandemic. While stopgaps serve an important purpose in maintaining federal operations, prolonged continuing resolutions create uncertainty that is disruptive to the long-term endeavor of medical research and impose unnecessary inefficiencies and delays in harnessing scientific opportunity toward the development of new treatments, diagnostics, preventive measures, and cures for patients.

Thanks in large part to the work of appropriators on both sides of the aisle, the national commitment to medical research in recent years has been resounding, and FY 2022 offers an opportunity to build on that momentum. The Ad Hoc Group urges lawmakers to work in a bipartisan manner to finalize, without any further delay, an FY 2022 spending bill that provides at least the House-passed $46.4 billion investment in the NIH base budget, as urged by over 300 members of the coalition in a Nov. 15 letter to appropriators. The cost of postponing investments in research is one that patients cannot afford.

*****

The Ad Hoc Group for Medical Research is a coalition of nearly 400 patient and voluntary health groups, medical and scientific societies, academic and research organizations, and industry. The Ad Hoc Group has one mission: to enhance the federal investment in biomedical, behavioral, social, and population-based research by increasing the funding for the National Institutes of Health.